Photo by youssefnaddam from unsplash
Oncologists and precision medicine teams have become the stars of lung cancer treatment. As our understanding of the heterogeneity of the molecular drivers and of the immune landscape of individual… Click to show full abstract
Oncologists and precision medicine teams have become the stars of lung cancer treatment. As our understanding of the heterogeneity of the molecular drivers and of the immune landscape of individual patient’s tumors becomes more nuanced, it is now clearer that a one-size-fits-all approach for the treatment of advanced lung cancer makes little sense. Instead, treatment is based upon histology, driver mutations, and immune markers. With that foundation, practice-changing trials of targeted therapies are being reported at a dizzying pace.
Journal Title: Journal of thoracic disease
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!